In part 2 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the results of the Viactye trial as shared at a recent opinion leaders meeting.

In part 3 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the remaining challenges in the work with stem cell-derived beta cells.

In part 4 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the move beyond academic labs to researchers in other arenas in the study of stem cell technology.

In part 5 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the work to resolve some of the challenges in stem cell-derived beta cell research.

In 2016, death rates were 29.1 versus 24.8 per 100,000 population

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for August 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Medical Bills …

Last week, we celebrated my daughter’s 31st birthday and this week we have a couple of articles related to her. I was looking for a nice blouse that she had in mind and was in H&M in the mall. While looking in the women’s department, I saw a mom with …

After reviewing evidence, a tool to evaluate benefit and risk has been developed for the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Assessing the costs of not following cholesterol treatment and possible ways to reverse non-adherence

Patients diagnosed before 10 years of age show increased risk of mortality and cardiovascular disease than those diagnosed at an older age.